January 26th 2024
A recent study unveiled the sustained safety and efficacy of relugolix combination therapy over 2 years.
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
‘Add-back’ therapy for teens with endometriosis?
July 13th 2017Results of a small new trial performed in a pediatric gynecology clinic show that an endometriosis therapy previously studied only in adults may be effective for teens. The findings reflect outcomes for quality of life in adolescents treated with “add-back” therapy with norethindrone acetate (NA) plus conjugated estrogens (CEE) versus NA alone.
Read More
Endometriosis and cancer-driver mutations
May 23rd 2017A genomic analysis of endometriotic lesions shows that a disease associated with almost no risk of malignant transformation may harbor mutations associated with cancer. The findings, published in NEJM, provide a rationale for characterizing all endometriosis subtypes, say the authors.
Read More
Elagolix dosage and impact on endometriosis
May 23rd 2017New research on two different dosages of elagolix show that both doses improved dysmenorrhea and nonmenstrual pelvic pain in women with endometriosis. The findings, published in NEJM, add to data from previous studies of the drug, which showed that it produced partial to nearly full estrogen suppression.
Read More